Methylene blue (methylthioninium chloride) is a synthetic compound licensed in the UK for treating methaemoglobinaemia, a rare blood disorder. Whilst it has been used in medicine for over a century, recent laboratory research has explored whether methylene blue might influence liver metabolism and fatty liver disease. However, it is crucial to understand that methylene blue is not approved or recommended for treating fatty liver in the UK. This article examines the current evidence, safety considerations, and established treatment options for fatty liver disease, helping you understand what works and what remains unproven.

What Is Methylene Blue and How Does It Work?

Methylthioninium chloride (commonly known as methylene blue) is a synthetic compound with a long history in medicine, first synthesised in 1876. It belongs to a class of chemicals known as phenothiazines and has been used for over a century in various clinical applications. In the UK, methylthioninium chloride is licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) under the brand name Proveblue, primarily for treating methaemoglobinaemia—a rare condition where haemoglobin cannot effectively release oxygen to body tissues.

The compound works through several distinct mechanisms. As a redox agent, methylthioninium chloride can accept and donate electrons, which allows it to restore normal haemoglobin function in methaemoglobinaemia. In laboratory studies, low doses have been shown to act as an electron carrier in the mitochondrial electron transport chain, though whether this translates to clinically meaningful benefits in humans remains unproven. This property has sparked interest in possible applications beyond its licensed indications, including neurological and metabolic conditions, but evidence in humans is inconclusive.

Methylthioninium chloride also demonstrates antioxidant properties at certain concentrations in experimental models, potentially helping to neutralise harmful free radicals that can damage cells. Conversely, at higher concentrations, it may exhibit pro-oxidant effects. The compound can cross the blood-brain barrier and has been investigated for cognitive effects, though robust clinical evidence is lacking. Its antimicrobial properties have been utilised in pathogen inactivation of plasma—methylene blue–treated fresh frozen plasma is used in UK transfusion practice to reduce the risk of transmitting infections.

In recent years, researchers have explored whether methylthioninium chloride might influence metabolic pathways relevant to liver function and fat metabolism in preclinical models. However, it is crucial to note that methylthioninium chloride is not currently licensed or recommended for treating fatty liver disease in the UK. Any use outside its approved indications would be considered off-label and should only occur under specialist medical supervision within appropriate clinical trials or research settings.

Understanding Fatty Liver Disease: Causes and Symptoms

Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. In the UK, this condition affects an estimated 20–30% of the general population, making it one of the most common liver disorders. The condition is broadly classified into two main categories: non-alcoholic fatty liver disease (NAFLD) and alcohol-related fatty liver disease. (Note: emerging international terminology uses metabolic dysfunction-associated steatotic liver disease [MASLD], though NAFLD remains widely used in UK practice.)

NAFLD develops in people who drink little or no alcohol and is strongly associated with metabolic risk factors. The primary causes include obesity, type 2 diabetes, insulin resistance, high cholesterol, and metabolic syndrome. Excess caloric intake, particularly from refined carbohydrates and saturated fats, contributes significantly to fat accumulation in hepatocytes. Genetic factors also play a role, with certain gene variants increasing susceptibility to fat storage in the liver.

Most individuals with simple fatty liver experience no symptoms in the early stages, which is why the condition is often discovered incidentally during imaging for other reasons. When symptoms do occur, they may include persistent fatigue, discomfort in the upper right abdomen, and general malaise. As the condition progresses to non-alcoholic steatohepatitis (NASH)—where inflammation and liver cell damage occur—patients may develop more concerning signs.

Progressive liver disease can lead to fibrosis (scarring), cirrhosis, and ultimately liver failure or hepatocellular carcinoma. According to NICE guidance (NG49), patients with NAFLD should be assessed using a stepwise approach: first with non-invasive scoring systems such as the FIB-4 score or NAFLD Fibrosis Score (using age-adjusted cut-offs), then with the Enhanced Liver Fibrosis (ELF) blood test if initial scores suggest possible advanced fibrosis. Patients with an ELF score of 10.51 or above should be referred to a hepatologist. Transient elastography (FibroScan) may be arranged in specialist settings to assess liver stiffness, though thresholds vary by local protocol. Early identification is crucial because lifestyle interventions can prevent progression, whilst advanced disease requires specialist hepatology input and monitoring for complications including portal hypertension and liver cancer.

Potential Benefits and Mechanisms in Liver Health

Research into methylthioninium chloride's effects on liver health remains largely experimental and preclinical, with most evidence derived from laboratory and animal studies rather than human clinical trials. Several proposed mechanisms have generated scientific interest, though it is essential to emphasise that there is currently no established link between methylthioninium chloride use and effective treatment of fatty liver disease in humans.

In animal models, methylthioninium chloride has demonstrated potential to enhance mitochondrial function within hepatocytes. Since mitochondrial dysfunction contributes to the progression from simple steatosis to steatohepatitis, improving mitochondrial efficiency could theoretically reduce oxidative stress and inflammation in the liver. Some laboratory studies have suggested effects on cellular energy metabolism and fat oxidation pathways, though these findings remain hypothetical and have not been confirmed in robust human trials.

Additionally, antioxidant properties observed at specific doses in experimental settings might help counteract the oxidative stress that characterises NASH. Oxidative stress occurs when reactive oxygen species overwhelm the liver's natural antioxidant defences, leading to lipid peroxidation and cellular damage. By acting as an alternative electron acceptor in laboratory models, methylthioninium chloride might reduce the production of these harmful molecules, though clinical relevance is unproven.

Some preclinical evidence suggests methylthioninium chloride may influence lipid metabolism pathways, potentially affecting how the liver processes and stores fats in experimental conditions. However, these findings have not been replicated in high-quality human clinical trials, and the optimal dosing, safety profile, and long-term effects in liver disease remain unknown.

Important caveat: No high-quality randomised controlled trials have established methylthioninium chloride as an effective treatment for fatty liver disease in humans. The European Medicines Agency (EMA) and MHRA have not approved methylthioninium chloride for this indication. Patients should not self-prescribe or use methylthioninium chloride for liver conditions outside of approved clinical trials or specialist supervision, as inappropriate use may cause harm.

Safety Considerations and Side Effects of Methylene Blue

Whilst methylthioninium chloride has an established safety profile when used appropriately for its licensed indication, it is not without risks, and several important safety considerations must be understood. The compound can cause various adverse effects, some of which may be serious, particularly when used at inappropriate doses or in vulnerable populations.

Common side effects include blue or green discolouration of urine, which is harmless but can be alarming if unexpected. Patients may also experience nausea, vomiting, abdominal pain, dizziness, headache, and sweating. Some individuals report a blue-green tint to their skin, particularly at higher doses. These effects are generally reversible upon discontinuation.

Serious adverse reactions require immediate medical attention. Methylthioninium chloride can cause serotonin syndrome when combined with serotonergic medications. This occurs because methylthioninium chloride is a reversible inhibitor of monoamine oxidase A (MAO-A). Serotonin syndrome is potentially life-threatening and manifests as confusion, agitation, rapid heart rate, high blood pressure, dilated pupils, muscle rigidity, and hyperthermia. Patients taking selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tramadol, or other serotonergic medicines should not use methylthioninium chloride without specialist consultation and careful risk assessment.

Methylthioninium chloride is contraindicated in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, as it can trigger severe haemolytic anaemia. High doses may also cause haemolysis even in patients without G6PD deficiency. The compound should be avoided in pregnancy unless the situation is life-threatening and no safer alternative exists. Breastfeeding should be interrupted after treatment; consult the Summary of Product Characteristics (SmPC) for specific guidance on duration. Neonates and infants are particularly vulnerable to adverse effects, and use should be restricted to specialists.

Patients with severe renal impairment require caution, as the kidneys primarily excrete the compound; specialist advice should be sought and the lowest effective dose used. Methylthioninium chloride may interfere with pulse oximetry readings, giving falsely low oxygen saturation values.

Anyone considering methylthioninium chloride for any purpose should consult their GP or specialist. Never purchase methylthioninium chloride from unregulated sources, as purity and concentration cannot be guaranteed, potentially leading to toxicity or contamination with harmful substances. If you experience any side effects, report them via the MHRA Yellow Card scheme at www.mhra.gov.uk/yellowcard or search for 'Yellow Card' in the Google Play or Apple App Store.

Treatment Options for Fatty Liver Disease in the UK

The cornerstone of managing fatty liver disease in the UK follows evidence-based NICE guidance (NG49), which emphasises lifestyle modification as the primary therapeutic approach. Currently, no medications are specifically licensed for treating NAFLD, making non-pharmacological interventions the mainstay of care.

Weight loss represents the most effective intervention for patients with NAFLD who are overweight or obese. NICE recommends a target of 7–10% body weight reduction, which has been shown to improve liver fat content, inflammation, and even fibrosis in some cases. This should be achieved gradually through a combination of reduced caloric intake and increased physical activity. The NHS provides access to weight management programmes, and some patients may be eligible for specialist tier 3 services or bariatric surgery if they meet specific criteria.

Dietary modifications should focus on reducing intake of refined carbohydrates, saturated fats, and sugar-sweetened beverages whilst increasing consumption of vegetables, fruits, whole grains, and lean proteins. The Mediterranean diet pattern has demonstrated particular benefit in reducing hepatic steatosis. Regarding alcohol, patients should follow UK Chief Medical Officers' low-risk drinking guidelines: no more than 14 units per week, spread over 3 or more days, with several alcohol-free days. In patients with steatohepatitis or advanced fibrosis, specialists may advise complete abstinence.

Physical activity recommendations include at least 150 minutes of moderate-intensity aerobic exercise weekly, such as brisk walking, cycling, or swimming, in line with NHS physical activity guidelines. Resistance training should also be incorporated. Exercise benefits liver health independently of weight loss.

Management of comorbidities is essential. Optimising control of type 2 diabetes, hypertension, and dyslipidaemia reduces cardiovascular risk, which is the leading cause of mortality in NAFLD patients. Medications such as metformin, statins, and antihypertensives should be used according to standard guidelines. Statins are safe in NAFLD and should not be withheld due to concerns about liver disease.

Risk stratification and specialist referral: NICE NG49 recommends a stepwise approach. All patients with suspected NAFLD should have their risk of advanced fibrosis assessed using the FIB-4 score or NAFLD Fibrosis Score, applying age-adjusted cut-offs. If these scores suggest possible advanced fibrosis, an Enhanced Liver Fibrosis (ELF) blood test should be arranged. Patients with an ELF score of 10.51 or above, or those with features of cirrhosis or persistently abnormal liver function tests despite lifestyle intervention, should be referred to hepatology. Transient elastography may be used in specialist settings as part of comprehensive assessment, though protocols vary.

Seek urgent medical attention (via NHS 111, your GP, or A&E depending on severity) if you develop warning signs of decompensated liver disease: jaundice (yellowing of skin or eyes), abdominal swelling (ascites), confusion or altered mental state, vomiting blood or passing black tarry stools, or unexplained bruising or bleeding. These symptoms may indicate serious complications requiring immediate specialist assessment.

Frequently Asked Questions